MARK1 and adenocarcinoma: As is typical for patients with NSCLC, the SU2C-MARK cohort consisted predominantly of adenocarcinoma (73%) and squamous cell carcinoma (20%), with smaller contributions from large cell neuroendocrine (LCNE) carcinoma (2%) and other histologies (4%; Extended Data Fig. 1a).